## 505514206 06/07/2019 PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5561011

SUBMISSION TYPE:		NEW ASSIGNMENT				
NATURE OF CONVEYANCE:		ASSIGNMENT				
CONVEYING PARTY DA	ATA					
		Name	Execution Date			
HARROW HEALTH, INC			03/14/2019			
RECEIVING PARTY DA	та					
Name:	MELT PHARMACEUTICALS, INC.					
Street Address:	12264 EL CAMINO REAL, SUITE 350					
City:	SAN DIEGO					
State/Country:		CALIFORNIA				
Postal Code:	92130					
		32130				
PROPERTY NUMBERS	Total: 9					
Property Type		Number	7			
Application Number:	6218	2130	-			
		5184768				
		5903529				
Application Number:		3615	-			
••		5875	-			
		1973	-			
		0450	-			
		S1637893				
PCT Number:	US19	934034	-			
CORRESPONDENCE D						
Fax Number:	. ,	374-2089				
		e-mail address first; if that is un bat is unsuccessful, it will be se				
Phone:	er, if provided; if that is unsuccessful, it will be sent via US Mail. 8585924141					
Email:	dock	docketing@wageniplaw.com, antony@wageniplaw.com,				
_	aj@v	aj@wageniplaw.com				
Correspondent Name:		WAGENKNECHT IP LAW GROUP PC				
Address Line 1:		12396 WORLD TRADE DRIVE, SUITE 312				
Address Line 4:	SAN	SAN DIEGO, CALIFORNIA 92128				
ATTORNEY DOCKET NUMBER:		20610-000000				
AME OF SUBMITTER:		ALLEN ISABELO				
		<u> </u>	PATENT			

SIGNATURE:	/Allen Isabelo/			
DATE SIGNED:	06/07/2019			
Total Attachments: 2				
source=20243 Assignment (Harrow to Melt)#page1.tif				
source=20243 Assignment (Harrow to Melt)#page2.tif				

## PATENT ASSIGNMENT

The undersigned (hereinafter collectively referred to as the Assignor), in consideration of the sum of one US dollar (\$ 1.00) and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, hereby sell, assign, and transfer to:

## MELT PHARMACEUTICALS, INC.

(hereinafter referred to as the Assignee), of:

## 12264 El Camino Real, Suite 350 San Diego, CA 92130 US

the entire right, title, and interest in and to the following patent applications:

Country	Application No.	Patent No.	Filing Date
US	62/182,130		June 19, 2015
US	15/184,768	9,918,993	June 16, 2016
US	15/903,529	10,166,240	February 23, 2018
US	15/903,615	10,179,136	February 23, 2018
US	15/995,875		June 1, 2018
US	16/021,973		June 28, 2018
US	16/250,450		January 17, 2019
WO	PCT/US2016/037893		June 16, 2016
AU	2016280161		June 16, 2016
CA	2,989,319	2,989,319	June 16, 2016
EP	16812447.7		June 16, 2016
JP	2017-566010		June 16, 2016
KR	10-2018-7000815		June 16, 2016
HK	18112868.4	~~~	June 16, 2016
JP	2019-010699		June 16, 2016

and in any and all patent application(s) claiming benefit of priority thereto, including any international patent application filed under the Patent Cooperation Treaty (PCT), any regional patent application, and any national patent application (as well as any continuation, divisional, continuation-in-part or substitute patent application), filed in any country in the world; the right, title and interest to be held and enjoyed by the Assignee for his own use, and for his own legal representatives and assigns, for the full term for which patents are granted.

The Assignor hereby agrees to execute all papers necessary in connection with the filing and prosecution of any patent application (including any international patent application, national or regional patent application, continuation, divisional or continuation-in-part patent application) claiming priority to said United States Patent Application including but not limited to any declaration of inventorship, and also agrees to execute separate assignments in connection with such applications as the Assignce may deem necessary or expedient. The Assignor hereby represents to have full right to convey the interest herein assigned, and has not executed, and will not execute, any agreement in conflict therewith.

The Assignor hereby grants the Practitioners associated with United States Patent and Trademark Office (USPTO) Customer Number 59538 assigned to Wagenknecht IP Law Group, PC power to insert in this assignment and any further identification that may be necessary or desirable in order to comply with the rules of the USPTO for recordation of this document.

Acknowledgement of Assignor:

Harrow Health, Inc. 3/14/2019

Mark L. Baum Chief Executive Officer Harrow Health, Inc.

Date

This Assignment is accepted by Melt Pharmaceuticals, Inc.

Signature:

Greg Madison

DocuSigned by:

Gregory Madison Chief Executive Officer Melt Pharmaceuticals, Inc.

**RECORDED: 06/07/2019**